BeOne Medicines AG (ONC)
$349.08-0.38%Close
SELLBEAR · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $37.3B
- Beta
- 0.52
- P/E (TTM)
- 24.39
- Short % float
- 2.88%
- Days to cover
- 5.0
- SI change
- +13.2%
- 1W
- -3.78%
- 1M
- -1.34%
- vs SPY 1W
- -3.64%
- vs SPY 1M
- -3.85%
Industry peers
FMP comparable companies · ranked by market cap
- 600276.SSJiangsu Hengrui Medicine Co., Ltd.$298.9B$46.85
- 1801.HKInnovent Biologics, Inc.$161.3B$92.65
- 6990.HKSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.$103.7B$444.60
- 688331.SSRemeGen Co. Ltd. Class A$59.7B$107.86
- 688578.SSShanghai Allist Pharmaceuticals Co., Ltd.$37.1B$82.50
- 688180.SSShanghai Junshi Biosciences Co., Ltd.$34.5B$33.83
- 688266.SSSuzhou Zelgen Biopharmaceuticals Co., Ltd.$27.6B$104.25
- 688837.SSEvopoint Biosciences Co. Ltd.$23.7B$47.25
- 300558.SZBetta Pharmaceuticals Co., Ltd.$20.5B$48.43
- 688062.SSMabwell (Shanghai) Bioscience Co., Ltd.$9.9B$24.78
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on ONC?
- LOPJLB’s latest quantitative signal on BeOne Medicines AG (ONC) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is ONC in?
- BeOne Medicines AG (ONC) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does BeOne Medicines AG (ONC) do?
- BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The companyâs commercial stage products include BRUKINSA, a small molecule inhibitor of Brutonâs Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the …